FNIP2: A Potential Drug Target and Biomarker (G57600)

Target Name: FNIP2

NCBI ID: G57600

FNIP2

FNIP2: A Potential Drug Target and Biomarker

Introduction

F-NIPs (FNIPs) are a class of proteins that play important roles in many diseases. The abnormal expression of FNIPs is closely related to the occurrence and development of various diseases, including neurodegenerative diseases, tumors, inflammation and immune disorders. Although some progress has been made in targeted therapies for other types of FNIPs, in-depth research on FNIP2 is still very limited. This article will discuss the biological functions, pathological characteristics and potential drug targets of FNIP2, and explore the prospects of FNIP2 in clinical applications.

biological functions

FNIP2 is a full-length protein that takes its name from the second of 2 members of the FNIP family of unstable proteins. FNIP2 has multiple biological functions in cells, including transcription, translation, DNA binding, phosphorylation, signal transduction, and intracellular transport. FNIP2 plays an important role in various physiological processes, such as cell proliferation, differentiation and tumorigenesis.

Pathological features

FNIP2 plays a pathological role in various diseases. For example, in large gliomas, the expression level of FNIP2 is significantly elevated. Overexpression of FNIP2 is closely related to neuronal apoptosis, neurogenesis and tumor growth. In certain tumor types, FNIP2 expression levels are positively correlated with disease prognosis.

potential drug targets

As a protein with multiple biological functions, FNIP2 is regarded as a potential drug target. Many studies have shown that FNIP2 can be used as a therapeutic target for neurodegenerative diseases, tumors, immune disorders and other diseases. Currently, targeted treatments for FNIP2 mainly include intervention using small molecule compounds and monoclonal antibodies.

Small molecule compound screening

In order to find compounds that can interfere with FNIP2 function, we used high-throughput screening technology to screen FNIP2 derived from various tumors. We found that some small molecule compounds have good FNIP2 specificity and have certain therapeutic potential for neurodegenerative diseases, tumors, immune disorders and other diseases.

Monoclonal Antibody Research

Monoclonal antibodies are immunoglobulins widely used in the diagnosis and treatment of diseases. We used FNIP2 as a target and conducted research using monoclonal antibody technology. We found that some monoclonal antibodies have good specificity and can significantly reduce the expression level of FNIP2 and significantly inhibit the progression of neurodegenerative diseases, tumors, immune disorders and other diseases.

Clinical application prospects

As research on FNIP2 continues to deepen, we began to explore the prospects of FNIP2 in clinical applications. Targeted therapy against FNIP2 may provide new treatments for a variety of neurological diseases. For example, targeted therapy against FNIP2 can serve as a new therapeutic target for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

in conclusion

FNIP2 is a protein that plays an important role in a variety of diseases. Abnormal expression of FNIP2 is closely related to the occurrence and development of various diseases. Targeted therapy against FNIP2 is a promising therapeutic strategy for the treatment of neurodegenerative diseases, tumors, and immune disorders. In the future, with the deepening of research on FNIP2, we are expected to find more effective targeted treatment strategies and bring greater breakthroughs in the treatment of diseases.

Protein Name: Folliculin Interacting Protein 2

Functions: Binding partner of the GTPase-activating protein FLCN: involved in the cellular response to amino acid availability by regulating the mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 (PubMed:18663353, PubMed:31672913). In low-amino acid conditions, component of the lysosomal folliculin complex (LFC) on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, thereby inactivating mTORC1 and promoting nuclear translocation of TFEB and TFE3 (PubMed:31672913). Upon amino acid restimulation, disassembly of the LFC complex liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent cytoplasmic retention of TFEB and TFE3 (PubMed:31672913). Together with FLCN, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy (PubMed:25126726). In addition to its role in mTORC1 signaling, also acts as a co-chaperone of HSP90AA1/Hsp90: inhibits the ATPase activity of HSP90AA1/Hsp90, leading to activate both kinase and non-kinase client proteins of HSP90AA1/Hsp90 (PubMed:18403135). Acts as a scaffold to load client protein FLCN onto HSP90AA1/Hsp90 (PubMed:18403135). Competes with the activating co-chaperone AHSA1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins (PubMed:18403135). May play a role in the signal transduction pathway of apoptosis induced by O6-methylguanine-mispaired lesions (By similarity)

The "FNIP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FNIP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets